[Skip to Content]
[Skip to Content Landing]
Views 978
Citations 0
Clinical Trials Update
February 28, 2017

Crizanlizumab Prevents Sickle Cell Pain Crises

JAMA. 2017;317(8):798. doi:10.1001/jama.2017.0355

In a randomized trial of patients with sickle cell disease recently published in New England Journal of Medicine, the P-selectin inhibitor crizanlizumab resulted in a significantly lower rate of disease-related pain crises than placebo. Hydroxyurea is currently the only drug that modifies the natural history of the disease, but it doesn’t prevent pain crises.

The phase 2 trial assigned 198 patients with sickle cell disease in a 1:1:1 ratio to receive low-dose crizanlizumab (2.5 mg/kg of body weight), high-dose crizanlizumab (5.0 mg/kg), or placebo administered intravenously 14 times over 52 weeks. Approximately 40% of patients in each group were receiving concomitant hydroxyurea.

First Page Preview View Large
First page PDF preview
First page PDF preview
×